Andrzej Orzeszko Selected Research

4,5,6,7-tetrabromobenzimidazole

7/2012

Modified tetrahalogenated benzimidazoles with CK2 inhibitory activity are active against human prostate cancer cells LNCaP in vitro.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrzej Orzeszko Research Topics

Disease

5	Neoplasms (Cancer) 02/2018 - 11/2008
2	Prostatic Neoplasms (Prostate Cancer) 02/2018 - 07/2012
1	Leukemia 11/2010
1	Melanoma (Melanoma, Malignant) 05/2003

Drug/Important Bio-Agent (IBA)

2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 02/2018 - 11/2008
1	Antineoplastic Agents (Antineoplastics)IBA 02/2018
1	AndrogensIBA 02/2018
1	Protein Kinases (Protein Kinase)IBA 08/2014
1	Phosphotransferases (Kinase)IBA 07/2013
1	4,5,6,7-tetrabromobenzimidazoleIBA 07/2012
1	Hormones (Hormone)IBA 07/2012
1	BenzimidazolesIBA 07/2012
1	Cytostatic AgentsIBA 11/2010
1	Oncogene Proteins (Oncogene Protein)IBA 11/2010
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 11/2010
1	Casein Kinase II (Casein Kinase 2)IBA 11/2008
1	Zidovudine (Retrovir)FDA LinkGeneric 05/2003
1	ImidesIBA 05/2003
1	phthalimideIBA 05/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2003

Therapy/Procedure

1	Therapeutics 02/2018